Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GBA1 | P04062 | 9/20 | 0.64 |
| ▸ | GAA | P10253 | 2/20 | 0.64 |
| ▸ | GLB1 | P16278 | 2/20 | 0.64 |
| ▸ | PYGL | P06737 | 1/20 | 0.64 |
| ▸ | GBA2 | Q9HCG7 | 1/20 | 0.64 |
| ▸ | FUCA1 | P04066 | 4/20 | 0.55 |
| ▸ | GLA | P06280 | 2/20 | 0.55 |
| ▸ | MAN1B1 | Q9UKM7 | 1/20 | 0.46 |
| ▸ | GANAB | Q14697 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL587084 | 1.00 | GBA1 (0.64) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL6860363 | 1.00 | GBA1 (0.64) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL16998733 | 1.00 | GBA1 (0.64) | GBA1GAAGLB1PYGLGBA2 | |
| Hydrochloric Acid SCHEMBL3068490 | 0.98 | GBA1 (0.61) | GBA1GAAGLB1PYGLGBA2 | |
| Hydrochloric Acid SCHEMBL586769 | 0.98 | GBA1 (0.61) | GBA1GAAGLB1PYGLGBA2 | |
| Hydrochloric Acid SCHEMBL17074808 | 0.98 | GBA1 (0.61) | GBA1GAAGLB1PYGLGBA2 | |
| SCHEMBL7406340 | 0.85 | — | — | |
| Hydrochloric Acid SCHEMBL15719465 | 0.83 | — | — | |
| Hydrochloric Acid SCHEMBL15719464 | 0.83 | — | — | |
| SCHEMBL6856454 | 0.82 | GBA1 (0.59) | GBA1GAAGLB1PYGLGBA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2416656-B1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS INC (US) | 2015-12-23 | — | — | EP | claimed |
| US-8940766-B2 | Methods for preventing and/or treating lysosomal storage disorders | AMICUS THERAPEUTICS, INC. (US) | 2015-01-27 | — | — | US | claimed |
| EP-2416655-B1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS INC (US) | 2014-06-25 | — | — | EP | claimed |
| US-8304429-B2 | Methods for preventing and/or treating degenerative disorders of the central nervous system | AMICUS THERAPEUTICS, INC. (US) | 2012-11-06 | — | — | US | claimed |
| EP-2416656-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | Amicus Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | claimed |
| EP-2416655-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | Amicus Therapeutics, Inc. (US) | 2012-02-15 | — | — | EP | claimed |
| US-20100261753-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | US | claimed |
| WO-2010118283-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| WO-2010118282-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | WO | claimed |
| US-20100260740-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | AMICUS THERAPEUTICS, INC. (US) | 2010-10-14 | — | — | US | claimed |
| EP-1558245-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2005-08-03 | — | — | EP | claimed |
| WO-2004037233-A2 | USE OF GLYCOGEN PHOSPHORYLASE INHIBITORS FOR TREATMENT OF CARDIOVASCULAR DISEASES | NOVO NORDISK A/S (DK) | 2004-05-06 | — | — | WO | claimed |
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | NOVO NORDISK A/S (DK) | 2004-04-29 | — | — | US | claimed |
| US-20250136982-A1 | MODULATION OF ALPHA SYNUCLEIN EXPRESSION | IONIS PHARMACEUTICALS, INC. (US) | 2025-05-01 | — | — | US | disclosed |
| US-12043831-B2 | Modulation of alpha synuclein expression | IONIS PHARMACEUTICALS, INC. (US) | 2024-07-23 | — | — | US | disclosed |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | MODERNATX, INC. | 2022-06-16 | — | — | US | disclosed |
| EP-0749423-B1 | PIPERIDINES AND PYRROLIDINES | NOVO NORDISK AS (DK) | 2003-06-18 | — | — | EP | disclosed |
| US-5863903-A | ANTIDIABETIC AGENT | NOVO NORDISK A/S (DK) | 1999-01-26 | — | — | US | disclosed |
| EP-0749423-A1 | PIPERIDINES AND PYRROLIDINES | NOVO NORDISK A/S (DK) | 1996-12-27 | — | — | EP | disclosed |
| WO-1995024391-A1 | PIPERIDINES AND PYRROLIDINES | NOVO NORDISK A/S (DK) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082641-A1 | Use of glycogen phosphorylase inhibitors for treatment of cardiovascular diseases | PYGM, GYS1, AGL | GBA1 308/4885GAA 43/4885GLB1 198/4885 |
| US-20100261753-A1 | METHODS FOR PREVENTING AND/OR TREATING DEGENERATIVE DISORDERS OF THE CENTRAL NERVOUS SYSTEM | SNCA, BDNF, PARK7 | GBA1 71/4885GAA 1040/4885GLB1 1214/4885 |
| US-20100260740-A1 | METHODS FOR PREVENTING AND/OR TREATING LYSOSOMAL STORAGE DISORDERS | GBA1, GAA, MAN2B1 | GBA1 1/4885GAA 2/4885GLB1 38/4885 |
| US-20220184185-A1 | MRNA BASED ENZYME REPLACEMENT THERAPY COMBINED WITH A PHARMACOLOGICAL CHAPERONE FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS | GAA, GBA1, GBA2 | GBA1 2/4885GAA 1/4885GLB1 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.